Key result
Advanced congestive heart failure was associated with decreased circulating CML compared to controls (369.3 vs 467.8 ng/ml, p<0.01), whereas heart transplant recipients showed elevated CML.
Why the study?
How do circulating concentrations of advanced glycation end products differ between patients with severe congestive heart failure, heart transplant recipients, and healthy controls?
Cross-Sectional (n=72)
How do circulating concentrations of advanced glycation end products differ between patients with severe congestive heart failure, heart transplant recipients, and healthy controls?
Circulating advanced glycation end products are paradoxically decreased in severe heart failure due to lowered plasma proteins, but significantly elevated after heart transplantation, potentially related to immunosuppression and impaired renal function.
Decreased CML in advanced HF may confound AGE assessment; leaves open mechanisms and relevance post-transplant.
OBJECTIVES: To analyse circulating concentrations of advanced glycation end products (AGEs) in patients with severe congestive heart failure (CHF) and after heart transplantation; to identify the potential contribution of kidney function to plasma AGE concentrations; and to determine whether AGE concentrations and parameters of oxidative stress are interrelated. METHODS AND RESULTS: Circulating N(epsilon)-(carboxymethyl)lysine (CML) and AGE associated fluorescence (AGE-Fl), lipid peroxidation, and glomerular filtration rate (GFR) were measured in a cross sectional study of 22 patients with advanced CHF, 30 heart transplant recipients, and 20 healthy controls. Compared with the controls, the CHF patients had decreased CML (mean (SEM) 467.8 (20.0) ng/ml v 369.3 (22.3) ng/ml, p < 0.01), AGE-Fl (mean (SEM) 302.2 (13.3) arbitrary units v 204.9 (15.7) arbitrary units, p < 0.01), and GFR (p < 0.01). CML was positively related to decreased total protein and serum albumin and negatively to body mass index (p < 0.01). In contrast, in the heart transplant group, impaired GFR was associated with a notable rise of both CML (mean (SEM) 876.1 (53.1) ng/ml, p < 0.01) and AGE-Fl (mean (SEM) 385.6 (26.1) arbitrary units, p < 0.01). A positive relation between CML and serum albumin (r = 0.394, p < 0.05) and lipofuscin (r = 0.651, p < 0.01) was found. CONCLUSIONS: The contrasting concentration of CML and AGE-Fl between patients with CHF and after heart transplantation in the presence of decreased GFR and oxidative stress are explained by lowered plasma proteins in CHF and higher concentrations in heart transplant recipients. In heart transplant recipients, in addition to myocardial inflammatory processes, immunosuppression may be important for enhanced formation of AGEs.
No takes yet. Share an insight, caveat, or question.
A. Heidland (2004) conducted a cross-sectional in Congestive heart failure and heart transplantation (n=72). Advanced congestive heart failure vs. Healthy controls was evaluated on Circulating N(epsilon)-(carboxymethyl)lysine (CML) concentrations (p=<0.01). Advanced congestive heart failure was associated with decreased circulating CML compared to controls (369.3 vs 467.8 ng/ml, p<0.01), whereas heart transplant recipients showed elevated CML.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: